Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era
With wide availability of low-cost generics, primary prevention with statins has become less expensive. We projected the cost-effectiveness of expanded statin prescribing strategies using low-cost generics and identified conditions under which aggressive prescribing ceases to be cost-effective. We s...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 124; no. 2; pp. 146 - 153 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
12.07.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | With wide availability of low-cost generics, primary prevention with statins has become less expensive. We projected the cost-effectiveness of expanded statin prescribing strategies using low-cost generics and identified conditions under which aggressive prescribing ceases to be cost-effective.
We simulated expanded statin prescribing strategies with the coronary heart disease policy model, a Markov model of the US population >35 years of age. If statins cost $4/mo, treatment thresholds of low-density lipoprotein cholesterol >160 mg/dL for low-risk persons (0 to 1 risk factor), >130 mg/dL for moderate-risk persons (≥2 risk factors and 10-year risk <10%), and >100 mg/dL for moderately high-risk persons (≥2 risk factors and 10-year risk >10%) would reduce annual healthcare costs by $430 million compared with Adult Treatment Panel III guidelines. Lowering thresholds to >130 mg/dL for persons with 0 risk factors and >100 mg/dL for persons with 1 risk factor and treating all moderate- and moderately high-risk persons regardless of low-density lipoprotein cholesterol would provide additional health benefits for $9900 per quality-adjusted life-year. These findings are insensitive to most adverse effect assumptions (including statin-associated diabetes mellitus and severe hypothetical effects) but are sensitive to large reductions in the efficacy of statins or to a long-term disutility burden for which a patient would trade 30 to 80 days of life to avoid 30 years of statins.
Low-cost statins are cost-effective for most persons with even modestly elevated cholesterol or any coronary heart disease risk factors if they do not mind taking a pill daily. Adverse effects are unlikely to outweigh benefits in any subgroup in which statins are found to be efficacious. |
---|---|
AbstractList | With wide availability of low-cost generics, primary prevention with statins has become less expensive. We projected the cost-effectiveness of expanded statin prescribing strategies using low-cost generics and identified conditions under which aggressive prescribing ceases to be cost-effective.
We simulated expanded statin prescribing strategies with the coronary heart disease policy model, a Markov model of the US population >35 years of age. If statins cost $4/mo, treatment thresholds of low-density lipoprotein cholesterol >160 mg/dL for low-risk persons (0 to 1 risk factor), >130 mg/dL for moderate-risk persons (≥2 risk factors and 10-year risk <10%), and >100 mg/dL for moderately high-risk persons (≥2 risk factors and 10-year risk >10%) would reduce annual healthcare costs by $430 million compared with Adult Treatment Panel III guidelines. Lowering thresholds to >130 mg/dL for persons with 0 risk factors and >100 mg/dL for persons with 1 risk factor and treating all moderate- and moderately high-risk persons regardless of low-density lipoprotein cholesterol would provide additional health benefits for $9900 per quality-adjusted life-year. These findings are insensitive to most adverse effect assumptions (including statin-associated diabetes mellitus and severe hypothetical effects) but are sensitive to large reductions in the efficacy of statins or to a long-term disutility burden for which a patient would trade 30 to 80 days of life to avoid 30 years of statins.
Low-cost statins are cost-effective for most persons with even modestly elevated cholesterol or any coronary heart disease risk factors if they do not mind taking a pill daily. Adverse effects are unlikely to outweigh benefits in any subgroup in which statins are found to be efficacious. BACKGROUNDWith wide availability of low-cost generics, primary prevention with statins has become less expensive. We projected the cost-effectiveness of expanded statin prescribing strategies using low-cost generics and identified conditions under which aggressive prescribing ceases to be cost-effective.METHODS AND RESULTSWe simulated expanded statin prescribing strategies with the coronary heart disease policy model, a Markov model of the US population >35 years of age. If statins cost $4/mo, treatment thresholds of low-density lipoprotein cholesterol >160 mg/dL for low-risk persons (0 to 1 risk factor), >130 mg/dL for moderate-risk persons (≥2 risk factors and 10-year risk <10%), and >100 mg/dL for moderately high-risk persons (≥2 risk factors and 10-year risk >10%) would reduce annual healthcare costs by $430 million compared with Adult Treatment Panel III guidelines. Lowering thresholds to >130 mg/dL for persons with 0 risk factors and >100 mg/dL for persons with 1 risk factor and treating all moderate- and moderately high-risk persons regardless of low-density lipoprotein cholesterol would provide additional health benefits for $9900 per quality-adjusted life-year. These findings are insensitive to most adverse effect assumptions (including statin-associated diabetes mellitus and severe hypothetical effects) but are sensitive to large reductions in the efficacy of statins or to a long-term disutility burden for which a patient would trade 30 to 80 days of life to avoid 30 years of statins.CONCLUSIONSLow-cost statins are cost-effective for most persons with even modestly elevated cholesterol or any coronary heart disease risk factors if they do not mind taking a pill daily. Adverse effects are unlikely to outweigh benefits in any subgroup in which statins are found to be efficacious. |
Author | BIBBINS-DOMINGO, Kirsten PLETCHER, Mark J COXSON, Pamela G LAZAR, Lawrence D GOLDMAN, Lee |
Author_xml | – sequence: 1 givenname: Lawrence D surname: LAZAR fullname: LAZAR, Lawrence D organization: Cleveland Clinic Foundation, Cleveland, Ohio, United States – sequence: 2 givenname: Mark J surname: PLETCHER fullname: PLETCHER, Mark J organization: University of California, San Francisco, United States – sequence: 3 givenname: Pamela G surname: COXSON fullname: COXSON, Pamela G organization: University of California, San Francisco, United States – sequence: 4 givenname: Kirsten surname: BIBBINS-DOMINGO fullname: BIBBINS-DOMINGO, Kirsten organization: University of California, San Francisco, United States – sequence: 5 givenname: Lee surname: GOLDMAN fullname: GOLDMAN, Lee organization: Columbia University, New York, NY, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24366069$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21709063$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkF9LwzAUxYMouqlfQeqD-FTN_zSPo0wdDBWtz-U2S7DSNTPplH17Mzb16XIuv3Mu94zRYe97i9AlwTeESHJr2mDWHQyt7-Ed0g7f6EIyrg_QiAjKcy6YPkQjjLHOFaP0BI1j_EhSMiWO0QklCuskRqgqfRzyqXPWDO2X7W2MmXfZ65DS-6x6twFWm8z5kD2Hdglhk6ZN3PZ2lgjI5v4734b8eqYBztCRgy7a8_08RW9306p8yOdP97NyMs8Nl2zIFXd2ARwwlawRtCEghBPKaqEacMItHHMEG82FwgWjvGh44ThXApqGsmLBTtH1LncV_OfaxqFettHYroPe-nWsCyWpIFjKROodaYKPMVhXr3bv1ATX207rcvZSvs0n1ezpcfIwSTtc7zpN3ov9lXWztIs_52-JCbjaAxANdC5Ab9r4z3EmJZaa_QDwsIQF |
CODEN | CIRCAZ |
CitedBy_id | crossref_primary_10_1016_j_lanepe_2024_100887 crossref_primary_10_7326_M14_0027 crossref_primary_10_1186_s12872_016_0429_6 crossref_primary_10_1016_j_amjcard_2012_04_025 crossref_primary_10_1002_cncr_27980 crossref_primary_10_1007_s10557_015_6584_7 crossref_primary_10_1016_j_jacl_2013_06_004 crossref_primary_10_1371_journal_pone_0117182 crossref_primary_10_1097_SLA_0000000000001394 crossref_primary_10_1161_CIRCULATIONAHA_117_027067 crossref_primary_10_1007_s00228_013_1586_5 crossref_primary_10_1016_j_jacl_2020_09_001 crossref_primary_10_3389_fcell_2015_00057 crossref_primary_10_1016_S0001_4079_19_31605_X crossref_primary_10_1371_journal_pmed_1001361 crossref_primary_10_1042_CS20110449 crossref_primary_10_1186_1472_6904_12_13 crossref_primary_10_1586_14737167_2016_1136790 crossref_primary_10_3349_ymj_2017_58_1_82 crossref_primary_10_1093_ehjqcco_qcz001 crossref_primary_10_1371_journal_pone_0116377 crossref_primary_10_3390_jcm11216377 crossref_primary_10_1371_journal_pone_0285542 crossref_primary_10_3810_pgm_2014_11_2832 crossref_primary_10_3310_KLTR7714 crossref_primary_10_4236_abcr_2016_51002 crossref_primary_10_4236_wjcd_2023_134021 crossref_primary_10_1002_clc_22577 crossref_primary_10_1038_clpt_2014_86 crossref_primary_10_1136_bmjopen_2022_063800 crossref_primary_10_4236_wjcd_2018_87033 crossref_primary_10_1161_CIRCRESAHA_117_311849 crossref_primary_10_1016_j_cjca_2019_03_002 crossref_primary_10_1371_journal_pone_0164704 crossref_primary_10_1016_j_atherosclerosis_2014_12_059 crossref_primary_10_1210_jc_2018_02509 crossref_primary_10_1002_14651858_CD004816_pub5 crossref_primary_10_1007_s40273_015_0357_9 crossref_primary_10_1093_eurheartj_sux029 crossref_primary_10_1161_CIRCOUTCOMES_120_007485 crossref_primary_10_1177_0272989X17706081 crossref_primary_10_1007_s12181_012_0468_x crossref_primary_10_1038_nrcardio_2013_80 crossref_primary_10_2174_1570161116666180628145723 crossref_primary_10_3389_fmed_2023_1239737 crossref_primary_10_4236_wjcd_2022_126032 crossref_primary_10_1056_NEJMe1111558 crossref_primary_10_1016_j_jacc_2012_05_019 crossref_primary_10_18553_jmcp_2019_25_5_544 crossref_primary_10_1161_HYPERTENSIONAHA_115_06814 crossref_primary_10_1016_j_jvs_2013_04_048 crossref_primary_10_1161_CIRCULATIONAHA_115_019014 crossref_primary_10_1371_journal_pone_0069462 crossref_primary_10_1186_s12913_016_1420_8 crossref_primary_10_1186_s43044_024_00478_2 crossref_primary_10_1016_j_mjafi_2013_05_008 crossref_primary_10_1097_HCO_0b013e32836429e6 crossref_primary_10_1016_j_acra_2020_06_030 crossref_primary_10_1016_j_jacl_2021_12_001 crossref_primary_10_1186_s12916_022_02601_z crossref_primary_10_1016_j_surg_2015_02_030 crossref_primary_10_1586_erc_12_94 crossref_primary_10_7326_M14_1430 crossref_primary_10_1377_hlthaff_2013_0449 crossref_primary_10_1016_j_cjca_2012_11_032 crossref_primary_10_1177_2047487312448994 crossref_primary_10_1002_pds_4231 crossref_primary_10_1016_j_jacc_2021_08_065 crossref_primary_10_1007_s00268_015_3165_7 crossref_primary_10_1200_CCI_18_00097 crossref_primary_10_1038_nrneph_2013_104 crossref_primary_10_2217_clp_13_42 crossref_primary_10_4236_wjcd_2016_65012 crossref_primary_10_1016_j_jacc_2012_04_045 crossref_primary_10_1007_s11883_012_0229_0 crossref_primary_10_1111_jcmm_14879 crossref_primary_10_1161_CIRCRESAHA_118_313245 crossref_primary_10_1016_S0140_6736_12_60367_5 crossref_primary_10_2105_AJPH_2012_300755 crossref_primary_10_1016_j_nurpra_2012_12_009 crossref_primary_10_1891_2380_9418_9_1_108 crossref_primary_10_1001_jamacardio_2021_4987 crossref_primary_10_1161_CIRCULATIONAHA_117_032321 crossref_primary_10_1002_clc_22016 crossref_primary_10_1016_j_jval_2021_03_017 crossref_primary_10_1016_j_mcna_2017_03_001 crossref_primary_10_1371_journal_pmed_1002761 crossref_primary_10_1161_CIRCULATIONAHA_119_042956 crossref_primary_10_3390_ph17030289 crossref_primary_10_1111_j_1749_6632_2012_06478_x crossref_primary_10_1001_jamacardio_2019_2851 crossref_primary_10_1093_ajh_hpw047 crossref_primary_10_1016_j_amjcard_2012_04_003 crossref_primary_10_1016_j_pcad_2019_10_006 crossref_primary_10_1161_CIRCULATIONAHA_121_053678 crossref_primary_10_5334_gh_830 crossref_primary_10_1111_jcpt_12512 crossref_primary_10_3310_hsdr05160 crossref_primary_10_1093_jnci_djw281 crossref_primary_10_1016_j_jacl_2014_09_009 crossref_primary_10_1371_journal_pone_0169761 crossref_primary_10_1016_j_amjmed_2011_11_013 crossref_primary_10_4236_wjcd_2019_97043 crossref_primary_10_1007_s11883_014_0438_9 crossref_primary_10_1016_j_amjms_2021_12_011 crossref_primary_10_1186_s12963_016_0085_1 crossref_primary_10_1016_j_ejphar_2015_03_099 crossref_primary_10_1016_j_ajpc_2022_100371 crossref_primary_10_1016_j_amjcard_2017_07_068 |
Cites_doi | 10.1016/j.jacc.2010.05.018 10.1056/NEJM200206063462309 10.1177/0272989X9301300202 10.1056/NEJMoa0810177 10.1056/NEJM199701303360503 10.1016/j.amjcard.2005.12.010 10.1001/jama.279.20.1615 10.1345/aph.1D391 10.1016/S0002-9343(01)00793-8 10.1016/S0002-9149(02)02355-X 10.1056/NEJMoa0706201 10.1016/j.jacc.2009.12.057 10.1093/jnci/djh143 10.2105/AJPH.77.11.1417 10.1001/jama.288.4.455 10.1001/jama.288.4.462 10.1001/archinte.166.21.2307 10.1001/jama.282.24.2340 10.1161/01.CIR.101.2.207 10.1161/01.CIR.0000133317.49796.0E 10.1016/S0140-6736(09)61965-6 10.1001/jama.285.19.2486 10.7326/0003-4819-150-4-200902170-00005 10.1001/jama.1995.03520370074040 10.1016/S0140-6736(08)61240-4 10.1001/jama.1991.03460090093039 10.1056/NEJMoa043545 10.1016/S0140-6736(05)67394-1 10.7326/0003-4819-145-7-200610030-00010 10.1001/archinternmed.2010.182 10.1056/NEJMoa0807646 10.1067/mhj.2001.114805 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS |
Copyright_xml | – notice: 2015 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1161/circulationaha.110.986349 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 153 |
ExternalDocumentID | 10_1161_CIRCULATIONAHA_110_986349 21709063 24366069 |
Genre | Comparative Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 08R 0R~ 0ZK 18M 1CY 1J1 29B 2FS 2WC 354 40H 41~ 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAXR AAEJM AAGIX AAHPQ AAJCS AAMOA AAMTA AAPBV AAQKA AARTV AASOK AASXQ AAUGY AAWTL AAXQO AAYOK ABASU ABBUW ABDIG ABOCM ABPMR ABPTK ABQRW ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACOAL ACRKK ACRZS ACWDW ACWRI ACXNZ ADBBV ADCYY ADFPA ADGGA ADNKB AE3 AE6 AEBDS AEETU AENEX AFCHL AFDTB AFFNX AFUWQ AGINI AHMBA AHOMT AHRYX AHVBC AIJEX AJIOK AJJEV AJNWD AJNYG AKALU AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW ASPBG AVWKF AWKKM AYCSE AZFZN BAWUL BOYCO BQLVK BS7 BYPQX C1A C45 CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EEVPB EJD EX3 F2K F2L F2M F2N F5P FCALG FEDTE FL- FW0 GNXGY GQDEL GX1 H0~ H13 HZ~ H~9 IKREB IKYAY IN~ IPNFZ IQODW J5H JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI KQ8 L-C L7B M18 MVM N4W N9A NEJ N~7 N~B N~M O9- OAG OAH OBH OCB OCUKA ODA ODMTH OGEVE OHH OHT OHYEH OJAPA OK1 OL1 OLB OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ R58 RAH RHF RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WHG WOQ WOW X3V X3W X7M XXN XYM YFH YOC YQJ YSK YXB YYM YYP YZZ ZA5 ZFV ZGI ZXP ZY1 ZZMQN ~H1 AAAAV AAIQE AAUEB ABJNI ADHPY AFEXH AHQNM AINUH AJZMW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c463t-74feda4a0263b52b1a55f57e957baf5fdf3f10c9457083248b48f4475abb238d3 |
ISSN | 0009-7322 |
IngestDate | Fri Oct 25 00:18:55 EDT 2024 Fri Dec 06 03:51:20 EST 2024 Sat Sep 28 07:48:46 EDT 2024 Sun Oct 22 16:10:23 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Costs Enzyme Cardiovascular disease Statin derivative Cost benefit analysis Coronary heart disease Prevention coronary disease Treatment cost-benefit analysis Hydroxymethylglutaryl-CoA reductase hydroxymethylglutaryl-CoA reductase inhibitors Oxidoreductases Cost efficiency analysis Antilipemic agent |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c463t-74feda4a0263b52b1a55f57e957baf5fdf3f10c9457083248b48f4475abb238d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.1161/circulationaha.110.986349 |
PMID | 21709063 |
PQID | 876251066 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_876251066 crossref_primary_10_1161_CIRCULATIONAHA_110_986349 pubmed_primary_21709063 pascalfrancis_primary_24366069 |
PublicationCentury | 2000 |
PublicationDate | 2011-07-12 |
PublicationDateYYYYMMDD | 2011-07-12 |
PublicationDate_xml | – month: 07 year: 2011 text: 2011-07-12 day: 12 |
PublicationDecade | 2010 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 2011 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | 21747064 - Circulation. 2011 Jul 12;124(2):130-2 e_1_3_4_3_2 e_1_3_4_2_2 e_1_3_4_9_2 e_1_3_4_8_2 e_1_3_4_7_2 e_1_3_4_6_2 e_1_3_4_5_2 e_1_3_4_4_2 e_1_3_4_22_2 e_1_3_4_23_2 e_1_3_4_20_2 e_1_3_4_21_2 e_1_3_4_26_2 e_1_3_4_27_2 e_1_3_4_24_2 e_1_3_4_25_2 e_1_3_4_28_2 e_1_3_4_29_2 Illingworth DR (e_1_3_4_16_2) 1994; 16 e_1_3_4_30_2 e_1_3_4_11_2 e_1_3_4_34_2 e_1_3_4_12_2 e_1_3_4_33_2 e_1_3_4_32_2 e_1_3_4_10_2 e_1_3_4_31_2 e_1_3_4_15_2 e_1_3_4_37_2 e_1_3_4_13_2 e_1_3_4_36_2 e_1_3_4_14_2 e_1_3_4_35_2 e_1_3_4_19_2 e_1_3_4_17_2 e_1_3_4_18_2 |
References_xml | – ident: e_1_3_4_36_2 doi: 10.1016/j.jacc.2010.05.018 – ident: e_1_3_4_12_2 doi: 10.1056/NEJM200206063462309 – ident: e_1_3_4_20_2 doi: 10.1177/0272989X9301300202 – ident: e_1_3_4_33_2 doi: 10.1056/NEJMoa0810177 – ident: e_1_3_4_7_2 doi: 10.1056/NEJM199701303360503 – ident: e_1_3_4_17_2 doi: 10.1016/j.amjcard.2005.12.010 – ident: e_1_3_4_34_2 doi: 10.1001/jama.279.20.1615 – ident: e_1_3_4_15_2 doi: 10.1345/aph.1D391 – ident: e_1_3_4_24_2 doi: 10.1016/S0002-9343(01)00793-8 – ident: e_1_3_4_19_2 doi: 10.1016/S0002-9149(02)02355-X – ident: e_1_3_4_30_2 doi: 10.1056/NEJMoa0706201 – ident: e_1_3_4_37_2 doi: 10.1016/j.jacc.2009.12.057 – ident: e_1_3_4_22_2 – ident: e_1_3_4_25_2 doi: 10.1093/jnci/djh143 – ident: e_1_3_4_9_2 doi: 10.2105/AJPH.77.11.1417 – ident: e_1_3_4_27_2 doi: 10.1001/jama.288.4.455 – ident: e_1_3_4_28_2 doi: 10.1001/jama.288.4.462 – ident: e_1_3_4_26_2 doi: 10.1001/archinte.166.21.2307 – ident: e_1_3_4_3_2 doi: 10.1001/jama.282.24.2340 – ident: e_1_3_4_14_2 doi: 10.1161/01.CIR.101.2.207 – ident: e_1_3_4_4_2 doi: 10.1161/01.CIR.0000133317.49796.0E – volume: 16 start-page: 366 year: 1994 ident: e_1_3_4_16_2 article-title: A Review of Clinical Trials Comparing HMG-CoA reductase inhibitors publication-title: Clin Ther contributor: fullname: Illingworth DR – ident: e_1_3_4_18_2 doi: 10.1016/S0140-6736(09)61965-6 – ident: e_1_3_4_23_2 doi: 10.1001/jama.285.19.2486 – ident: e_1_3_4_5_2 doi: 10.7326/0003-4819-150-4-200902170-00005 – ident: e_1_3_4_6_2 doi: 10.1001/jama.1995.03520370074040 – ident: e_1_3_4_31_2 doi: 10.1016/S0140-6736(08)61240-4 – ident: e_1_3_4_10_2 doi: 10.1001/jama.1991.03460090093039 – ident: e_1_3_4_21_2 – ident: e_1_3_4_32_2 doi: 10.1056/NEJMoa043545 – ident: e_1_3_4_13_2 doi: 10.1016/S0140-6736(05)67394-1 – ident: e_1_3_4_35_2 doi: 10.7326/0003-4819-145-7-200610030-00010 – ident: e_1_3_4_29_2 doi: 10.1001/archinternmed.2010.182 – ident: e_1_3_4_11_2 doi: 10.1056/NEJMoa0807646 – ident: e_1_3_4_2_2 – ident: e_1_3_4_8_2 doi: 10.1067/mhj.2001.114805 |
SSID | ssj0006375 |
Score | 2.46268 |
Snippet | With wide availability of low-cost generics, primary prevention with statins has become less expensive. We projected the cost-effectiveness of expanded statin... BACKGROUNDWith wide availability of low-cost generics, primary prevention with statins has become less expensive. We projected the cost-effectiveness of... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 146 |
SubjectTerms | Adult Aged Biological and medical sciences Blood and lymphatic vessels Blood. Blood coagulation. Reticuloendothelial system Cardiology. Vascular system Cholesterol - blood Coronary Disease - drug therapy Coronary Disease - economics Costs and Cost Analysis Diabetes Mellitus - chemically induced Diabetes Mellitus - economics Diabetes Mellitus - therapy Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Medical sciences Middle Aged Models, Biological Pharmacology. Drug treatments Practice Guidelines as Topic Risk Factors Time Factors United States |
Title | Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era |
URI | https://www.ncbi.nlm.nih.gov/pubmed/21709063 https://search.proquest.com/docview/876251066 |
Volume | 124 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2UwytZuXXYpGoy9DGWxLcvRY-Z1TUaalDaBsBcj2RILtHZJHEr38_bLdmTZcbKm7PJigonkROfzuUjnfAehd4KC1adaEIgFBKEs5kRwRokKQBtKzzGMKibbYsh6E_p16k8bjZ9rWUvLXLbiH1vrSv5HqnAP5GqqZP9BsqtJ4QZ8BvnCFSQM17-ScZgtcmL5hyulZWpQzOl6anIpDF9AkUd4VnJKVIRNNr9RfBhkN8RMUo05not1bzWczeOyvde2rj1ruwiD7rfuua2zvrG8tatM4rPB8Tjs2YQLUxlUH0SFo-nFaGj92Ct1Keo-X5_6EJ4PL8jn0Wl_eDIqtNEM_NSybi2pt10D4tQx7Ta2iWKXYnZpUoE2NDQngWdrlVuqVMouJdS3pEcrrW1Lr0t4ums6uNrTtObcsVzEdy0FM5YirtdRfBemJqLFO8yzLKqb7Ny_Wc1VLqNLPQZRIH-AHhoyRtO_4WRapxkxL_Crbn7mf-2it-XjP9778A0f6fG1WMDrqm2flfsDocIhGj9Be2Ukg7sWlk9RQ6X76KCbijy7usXvcZFbXBza7KPd0zKF4wCN74IWZxpbAOIStBhAi0vQ4hq0GL4hcAXaagyA9hmafDEoI2VrDxJT5uUkoFolgoq2yzzpu9IRvq_9QHE_kEL7OtGedtoxp34AMYJLO5J2tOGmFFKCk5l4z9FOmqXqBcKBK6iWHZ7EQoJvT3kilQNuuaeYo3nbayK3Wszo2v7wqIh8mROF_fNwMrC0070u3GtHVgJNdLSx7KuRlbSbCFdyiEAhm1M2kapsuYiMewGGjrEmOrTyqQc7QZsDIl7-afZX6FH9Er1GO_l8qd6A85vLowJdvwDOYKrQ |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cost-Effectiveness+of+Statin+Therapy+for+Primary+Prevention+in+a+Low-Cost+Statin+Era&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=LAZAR%2C+Lawrence+D&rft.au=PLETCHER%2C+Mark+J&rft.au=COXSON%2C+Pamela+G&rft.au=BIBBINS-DOMINGO%2C+Kirsten&rft.date=2011-07-12&rft.pub=Lippincott+Williams+%26+Wilkins&rft.issn=0009-7322&rft.eissn=1524-4539&rft.volume=124&rft.issue=2&rft.spage=146&rft.epage=153&rft_id=info:doi/10.1161%2Fcirculationaha.110.986349&rft.externalDBID=n%2Fa&rft.externalDocID=24366069 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |